<DOC>
	<DOCNO>NCT00980395</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cladribine , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving bortezomib together cladribine rituximab may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together cladribine rituximab work treat patient advance mantle cell lymphoma indolent lymphoma .</brief_summary>
	<brief_title>Bortezomib , Cladribine , Rituximab Treating Patients With Advanced Mantle Cell Lymphoma Indolent Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year progression-free survival patient advance mantle cell lymphoma indolent lymphoma treat bortezomib , cladribine , rituximab . Secondary - Determine 2-year overall survival patient treat regimen . - Determine complete response overall response rate patient treat regimen . - Describe long- short-term toxicity regimen patient . - Determine prognostic importance Aurora kinase A patient treat regimen . - Determine cytokine profile lymphoma subtype change regimen . - Evaluate prognostic importance major carcinogenic pathway use tissue microarray . OUTLINE : Patients receive bortezomib IV day 1 4 , cladribine IV 2 hour day 1-5 , rituximab IV day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Blood sample collect baseline course 1 cytokine profile study . Previously collect tissue sample obtain analysis Aurora kinase A B , Ki-67 , cyclin D , Bcl-2 , phosphor-HisH3 , c-Met , VEGF expression use tissue microarray ( IHC stain ) , reverse transcriptase-PCR , and/or western blotting . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Voluntary consent performance studyrelated procedure Female subject either postmenopausal surgically sterilize willing use acceptable method birth control Male subject agree use acceptable method contraception duration study . Biopsyproven mantle cell , marginal zone , lymphoplasmacytic , small lymphocytic lymphoma , follicular lymphoma CD20positive disease Patients marginal zone , lymphoplasmacytic , small lymphocytic , follicular lymphoma least one criterion initiation treatment must meet : Symptomatic disease Cytopenia relate lymphoma Leukemic phase ( &gt; 5,000 malignant lymphocytes/µl ) Mass 5 cm great diameter For lymphoplasmacytic lymphoma : additional treatment criterion serum viscosity ≥ 4 cp , serum monoclonal protein &gt; 5 g/L , concurrent primary systemic AL amyloidosis , cold agglutinin disease Age 18 Prior treatment bortezomib and/or rituximab acceptable For follicular lymphoma , least one prior treatment Platelet count &lt; 100 X10 /L within 14 day enrollment , unless due bone marrow infiltration lymphoma , due autoimmune thrombocytopenia lymphoma . Patient absolute neutrophil count &lt; 1.0 X 10/L within 14 day registration , unless due bone marrow infiltration lymphoma . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day registration . ( Creatinine Clearance indicate Serum Creatinine . If Serum Creatinine abnormal , physician may due 24 hour urine clarify Creatinine Clearance . A 24 hour urine test require per study . ) Patient ≥ Grade 2 peripheral neuropathy within 14 day registration . Myocardial infarction within 6 month prior registration New York Heart Association ( NYHA ) Class III IV heart failure . uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant Patient receive investigational drug 14 day registration Serious medical psychiatric illness likely interfere study participation Diagnosed treat another malignancy within 3 year registration , w/ exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . CNS involvement lymphoma . Known HIVpositive . History disease refractory purine analog ( define remission duration &lt; 6 month therapy include fludarabine , pentostatin , cladribine ) . History intolerance bortezomib , boron , mannitol , cladribine , rituximab . Patient &gt; 1.5 X ULN Total Bilirubin Radiation therapy within 3 week randomization . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>extranodal marginal zone BCL mucosa assoc lymphoid tissue</keyword>
	<keyword>nodal marginal zone B Cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>